製品番号: HY-N0295

Protocatechualdehyde

(別名: Protocatechuic aldehyde; 3,4-ジヒドロキシベンズアルデヒド; Catechaldehyde; Rancinamycin IV)

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Protocatechualdehyde (Catechaldehyde), a natural polyphenol compound isolated from the roots of radix Salviae Miltiorrhizae, is associated with a wide variety of biological activities and has been widely used in medicine as an antioxidant, anti-aging, an antibacterial and anti-inflammatory agent.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.87%
CAS 番号: 139-85-5
分子式: C₇H₆O₃
分子量:138.12

保管条件:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Protocatechualdehyde 構造式

CAS 番号: 139-85-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	3.1 μM Compound: 17	Cytotoxicity against human A549 cells after 4 days by MTT assay Cytotoxicity against human A549 cells after 4 days by MTT assay	[PMID: 24359303]
A549	IC₅₀	>10 μM Compound: 22	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25710081]
A549	GI₅₀	42 μM Compound: 2	Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
B16-4A5	IC₅₀	17 μM Compound: 36	Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs	[PMID: 20189399]
Bel-7402	IC₅₀	3.7 μM Compound: 17	Cytotoxicity against human Bel7402 cells after 4 days by MTT assay Cytotoxicity against human Bel7402 cells after 4 days by MTT assay	[PMID: 24359303]
BMDM	IC₅₀	15 μM Compound: 6	Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-base	[PMID: 31257875]
BV-2	IC₅₀	>100 μM Compound: 26	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
DLD-1	IC₅₀	70 μM Compound: 4	Cytotoxicity against human DLD1 cells after 96 hrs by MTT assay Cytotoxicity against human DLD1 cells after 96 hrs by MTT assay	[PMID: 15387639]
DLD-1	IC₅₀	70 μmol Compound: 4	Cytotoxicity against human DLD1 cells after 96 hrs by MTT assay Cytotoxicity against human DLD1 cells after 96 hrs by MTT assay	[PMID: 15387639]
HBL-100	GI₅₀	>100 μM Compound: 2	Antiproliferative activity against human HBL100 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
HeLa	GI₅₀	49 μM Compound: 2	Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
HepG2 2.2.15	EC₅₀	2.46 μg/mL Compound: 61	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion by ELISA	[PMID: 24549242]
HepG2 2.2.15	EC₅₀	3.94 μg/mL Compound: 61	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion by ELISA Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion by ELISA	[PMID: 24549242]
HepG2 2.2.15	IC₅₀	4.17 μg/mL Compound: 61	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production by quantitative RT-PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV DNA production by quantitative RT-PCR analysis	[PMID: 24549242]
K562	IC₅₀	>10 μM Compound: 22	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 25710081]
KB	IC₅₀	>10 μM Compound: 17	Cytotoxicity against human KB cells after 4 days by MTT assay Cytotoxicity against human KB cells after 4 days by MTT assay	[PMID: 24359303]
N9	IC₅₀	>100 μM Compound: 31	Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 28073678]
SW1573	GI₅₀	54 μM Compound: 2	Antiproliferative activity against human SW1573 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
T47D	GI₅₀	>100 μM Compound: 2	Antiproliferative activity against human T47D cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]
WiDr	GI₅₀	>100 μM Compound: 2	Antiproliferative activity against human WiDr cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 25752525]

体外実験

Protocatechualdehyde (PCA) (50, 100 μM, 24/48 hours ) treated MCF-7 cells significantly decrease cell growth by 11% and 20% in 24 hours and by 22% and 27% in 48 hours, respectively^[2].
Protocatechualdehyde (50, 100 μM, 24 hours) treated MCF-7 cells are increased by 1.9-fold and 2.6-fold in the concentrations of 50 μM and 100 μM, respectively. PCA suppresses proliferation of estrogen receptor (ER)-positive (MCF-7) breast cancer cells, but not ER-negative (MDA-MB-231) breast cancer cells^[2].
Protocatechualdehyde (0, 100, 200 μM, 48 hours in HCT116 and SW480 cells) affects the enzyme activity of HDAC and observed that PCA treatment resulted in inhibition of HDAC activity in dose-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

Human breast cancer cell (MCF-7 and MDA-MB-231)
Concentration:

0, 5, 10, 25, 50, and 100 μM
Incubation Time:

24, 48 hours
Result:

Inhibited MCF-7 cells cell growth.

Apoptosis Analysis^[2]

Cell Line:

Human breast cancer cell (MCF-7 and MDA-MB-231)
Concentration:

0, 5, 10, 25, 50, and 100 μM
Incubation Time:

24, 48 hours
Result:

Increased apoptosis in MCF-7 cells.

化学情報

CAS 番号 139-85-5
性状 Solid
分子量 138.12
分子式 C₇H₆O₃
Color Light yellow to brown
SMILES

O=CC1=CC=C(O)C(O)=C1
別名

Protocatechuic aldehyde; 3,4-ジヒドロキシベンズアルデヒド; Catechaldehyde; Rancinamycin IV
Structure Classification
- Phenols
- Polyphenols
Initial Source
- Plants
- Labiatae
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (2)

All

Sort by:

Journal Impact Factor

Res Sq

2026 Apr 15.
Biomed Pharmacother

Multi-omics profiling reveals ortho-topolin riboside and protocatechualdehyde combination exhibits anti-proliferative activity by modulating metabolic pathways in in vitro and in vivo radio-resistant MDA-MB-231 cell models. [Abstract]

2025 Nov:192:118631. PMID: 41067076

溶剤 & 溶解度

体外:

DMSO : ≥ 50 mg/mL (362.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

7.2401 mL

36.2004 mL

72.4008 mL

5 mM

1.4480 mL

7.2401 mL

14.4802 mL

10 mM

0.7240 mL

3.6200 mL

7.2401 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (18.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (275 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Li S, et al. Evaluation of the Antibacterial Effects and Mechanism of Action of Protocatechualdehyde against Ralstonia solanacearum. Molecules. 2016 Jun 9;21(6). [Content Brief]

[2]. Choi J, et al. Anticancer activity of protocatechualdehyde in human breast cancer cells. J Med Food. 2014 Aug;17(8):842-8. [Content Brief]

[3]. Jeong JB, et al. Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. Biochem Biophys Res Commun. 2013 Jan 4;430(1):381-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	7.2401 mL	36.2004 mL	72.4008 mL	181.0020 mL
	5 mM	1.4480 mL	7.2401 mL	14.4802 mL	36.2004 mL
	10 mM	0.7240 mL	3.6200 mL	7.2401 mL	18.1002 mL
	15 mM	0.4827 mL	2.4134 mL	4.8267 mL	12.0668 mL
	20 mM	0.3620 mL	1.8100 mL	3.6200 mL	9.0501 mL
	25 mM	0.2896 mL	1.4480 mL	2.8960 mL	7.2401 mL
	30 mM	0.2413 mL	1.2067 mL	2.4134 mL	6.0334 mL
	40 mM	0.1810 mL	0.9050 mL	1.8100 mL	4.5251 mL
	50 mM	0.1448 mL	0.7240 mL	1.4480 mL	3.6200 mL
	60 mM	0.1207 mL	0.6033 mL	1.2067 mL	3.0167 mL
	80 mM	0.0905 mL	0.4525 mL	0.9050 mL	2.2625 mL
	100 mM	0.0724 mL	0.3620 mL	0.7240 mL	1.8100 mL

Keywords

Protocatechualdehyde

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Protocatechualdehyde

Natural Product Library Plus

Drug Fragment Library

Covalent Fragment Library

Multifunctional Covalent Fragment Library

MedChemExpress（MCE）の使用を引用している文献 Protocatechualdehyde

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Protocatechualdehyde

Natural Product Library Plus

Drug Fragment Library

Covalent Fragment Library

Multifunctional Covalent Fragment Library

MedChemExpress（MCE）の使用を引用している文献 Protocatechualdehyde

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Protocatechualdehyde 関連分類

HY-N0295 関連分類